Evaluating the Addition of Hemodiafiltration to EVLP - Impact on the Regeneration of Marginal Donor Lungs

Recruiting N/A Interventional Study
Lung Diseases
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
30 (estimated)
Sponsor
Medical University of Vienna · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The primary objective of the study is the evaluation of the effect of hemodiafiltration during ex vivo lung perfusion in marginal donor lungs, and its feasibility. The hypothesis of this study is that this therapy could stabilize perfusate electrolyte composition, remove toxins and waste products, normalize pH levels and prevent edema formation, thereby reconditioning marginal donor lungs for tran…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Marginal donor lungs according to the ISHLT criteria (18) * PaO2/FiO2 ratio \< 400 (with FiO2=1.0 and PEEP=5-8cmH2O) * Donor age ≥ 55 years * Smoking history ≥ 20 pack-years * Infiltrates in chest radiograph * Significant secretions in bronchoscopy * Organisms on …
Contacts

Panja M Boehm, MD

004314040056440

panja.boehm@meduniwien.ac.at

CONTACT

Alberto Benazzo, MD

004314040056440

alberto.benazzo@meduniwien.ac.at

CONTACT